Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Natasha Rekhtman's publication output changed over time?
ScholarIQpublication output · 2013–2021
Output grew0% over the shown period — from 1 works in 2013 to 1 in 2021.
1
1
2
1
1
4
1
1
20132014201520162017201820202021
What are the most-cited papers on Natasha Rekhtman?
ScholarIQmost cited works
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J. Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa Ho, Martin L. Miller, Natasha Rekhtman, André L. Moreira, Fawzia K. Ibrahim, Cameron Bruggeman, Billel Gasmi, Roberta Zappasodi, Yuka Maeda, Chris Sander, Edward B. Garon, Taha Merghoub, Jedd D. Wolchok, Ton N. Schumacher, Timothy A. Chan
Science. 20157,996 Citations
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers
Helena A. Yu, Maria E. Arcila, Natasha Rekhtman, Camelia S. Sima, Maureen F. Zakowski, William Pao, Mark G. Kris, Vincent A. Miller, Marc Ladanyi, Gregory J. Riely
Clinical Cancer Research. 20132,497 CitationsOPEN ACCESS
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Patrick M. Forde, Jamie E. Chaft, Kellie N. Smith, Valsamo Anagnostou, Tricia R. Cottrell, Matthew D. Hellmann, Marianna Zahurak, Stephen C. Yang, David R. Jones, Stephen Broderick, Richard J. Battafarano, Moises J. Velez, Natasha Rekhtman, Zachary T. Olah, Jarushka Naidoo, Kristen A. Marrone, Franco Verde, Haidan Guo, Jiajia Zhang, Justina X. Caushi, Hok Yee Chan, John-William Sidhom, Robert B. Scharpf, James R. White, Edward Gabrielson, Hao Wang, Gary L. Rosner, Valerie W. Rusch, Jedd D. Wolchok, Taha Merghoub, Janis M. Taube, Victor E. Velculescu, Suzanne L. Topalian, Julie R. Brahmer, Drew M. Pardoll
New England Journal of Medicine. 20182,154 CitationsOPEN ACCESS
The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
Andrew G. Nicholson, Ming‐Sound Tsao, Mary Beth Beasley, Alain Borczuk, Élisabeth Brambilla, Wendy A. Cooper, Sanja Đačić, Deepali Jain, Keith M. Kerr, Sylvie Lantuéjoul, Masayuki Noguchi, Mauro Papotti, Natasha Rekhtman, Giorgio V. Scagliotti, Paul Van Schil, Lynette M. Sholl, Yasushi Yatabe, Akihiko Yoshida, William D. Travis
Journal of Thoracic Oncology. 20211,534 CitationsOPEN ACCESS
Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
Hira Rizvi, Francisco Sánchez-Vega, Konnor La, Walid K. Chatila, Philip Jonsson, Darragh Halpenny, Andrew J. Plodkowski, Niamh M. Long, Jennifer L. Sauter, Natasha Rekhtman, Travis J. Hollmann, Kurt A. Schalper, Justin F. Gainor, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub, Jedd D. Wolchok, Alexandra Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila, Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, Matthew D. Hellmann
Journal of Clinical Oncology. 20181,431 CitationsOPEN ACCESS
Related on ScholarIQ
Memorial Sloan Kettering Cancer Center
Institution
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Paper
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers
Paper
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Paper
The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
Paper
Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
Paper